Capecitabine, a new prodrug form of 5-FU, is converted into inactive 5’-deoxy-5-fluorocytidine after oral administration, which is converted into 5’-deoxy-5-fluorouridine by cytidine deaminase in hepatocytes and tumor cells, and selectively converted into fluorouracil. The gene discussed is CDA; the disease is neoplasm.